Fennec制药公司提前偿还了1 300万美元的债务,将年度利息支付额减少了1 500万美元。 Fennec Pharmaceuticals repays $13M debt early, cutting annual interest payments by $1.5M.

Fennec制药公司提前偿还了1 300万美元的可兑换债务,将其债务总额减至约1 900万美元,每年节省约150万美元的利息。 Fennec Pharmaceuticals has repaid $13 million of its convertible debt early, reducing its total debt to about $19 million and saving around $1.5 million annually in interest payments. 此举还避免发行约160万股。 This move also avoids issuing about 1.6 million shares. 该公司以经林业发展局批准的PEDMARK药物为名,以减少儿科癌症病人的毒性风险,预计其现有资金将支助2026年前的业务。 The company, known for its FDA-approved drug PEDMARK for reducing ototoxicity risk in pediatric cancer patients, expects its current funds to support operations until 2026.